A new approach to weight loss is challenging one of the striking assumptions behind popular weight loss drugs.Â
In a recent study, published on April 15, 2026, the researchers assessed a drug that targets two other hormones. GIP and Glucagon.
According to the Cleveland Clinic’s researchers, initial results from a rodent study suggest the approach may lead to weight loss similar to, or even greater than, that achieved with GLP-1-targeting therapies. The entire team has agreed to conduct rigorous testing to ensure their findings are valid and reliable. One of the experts mentioned that the drug GLP-1 comes with specific side effects like nausea and vomiting. The manufacturers did not mention in their “statutory warning” section any side effects or possible risks. This encouraged them to conduct the testing for the benefit of people who use this medication as a weight loss medication.
Take Control of Your Health Today
Quickly check your symptoms and understand your prescriptions with our smart, easy-to-use AI tools.
In a second test, the researchers administered the GIP m-targeting medicine and glucagon, and found that the combination led to greater weight loss than either drug alone.Â
For more interesting news and updates on diet and weight management, follow Medipedia. We help you stay up to date on the latest news and developments in health, medication, and treatment practices.Â
Disclaimer:
This content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting or changing any medication or treatment.